0 590

Cited 8 times in

Distinct immunological properties of the two histological subtypes of adenocarcinoma of the ampulla of Vater

DC Field Value Language
dc.contributor.author최혜진-
dc.contributor.author장미-
dc.date.accessioned2019-05-29T05:06:12Z-
dc.date.available2019-05-29T05:06:12Z-
dc.date.issued2019-
dc.identifier.issn0340-7004-
dc.identifier.urihttps://ir.ymlib.yonsei.ac.kr/handle/22282913/169400-
dc.description.abstractAdenocarcinoma of the ampulla of Vater (AOV) is classified into intestinal type (IT) and pancreatobiliary type (PB); however, the immunological properties of these subtypes remain to be characterized. Here, we evaluated the clinical implications of PD-L1 expression and CD8+ T lymphocyte density in adenocarcinomas of the AOV and their potential association with Yes-associated protein (YAP). We analyzed 123 adenocarcinoma-of-the-AOV patients who underwent surgical resection, and tumors were classified into IT or PB type. Tumor or inflammatory cell PD-L1 expression, CD8+ T lymphocyte density in the cancer cell nest (intratumoral) or in the adjacent stroma, and YAP localization and intensity were analyzed using immunohistochemical staining. PB-type tumors showed higher tumoral PD-L1 expression than IT-type tumors, and tumoral PD-L1 expression was associated with a shorter disease-free survival (DFS) [hazard ratio (HR), 1.77; p = 0.045] and overall survival (OS) (HR 1.99; p = 0.030). Intratumoral CD8+ T lymphocyte density was higher in IT type than in PB type and was associated with a favorable DFS (HR 0.47; p = 0.022). The nuclear staining pattern of YAP in tumor cells, compared to non-nuclear staining patterns, was more frequently associated with PB type and increased tumoral PD-L1 expression. Nuclear YAP staining was a significant prognostic factor for OS (HR 2.21; p = 0.022). These results show that the two subtypes of adenocarcinoma of the AOV exhibit significant differences in tumoral PD-L1 expression and intratumoral CD8+ T lymphocyte density, which might contribute to their distinct clinical features.-
dc.description.statementOfResponsibilityrestriction-
dc.languageEnglish-
dc.publisherSpringer Verlag-
dc.relation.isPartOfCANCER IMMUNOLOGY IMMUNOTHERAPY-
dc.rightsCC BY-NC-ND 2.0 KR-
dc.rightshttps://creativecommons.org/licenses/by-nc-nd/2.0/kr/-
dc.subject.MESHAdenocarcinoma/immunology*-
dc.subject.MESHAdenocarcinoma/mortality-
dc.subject.MESHAdenocarcinoma/pathology-
dc.subject.MESHAged-
dc.subject.MESHAmpulla of Vater*-
dc.subject.MESHB7-H1 Antigen/analysis-
dc.subject.MESHCD8-Positive T-Lymphocytes/immunology-
dc.subject.MESHCommon Bile Duct Neoplasms/immunology*-
dc.subject.MESHCommon Bile Duct Neoplasms/mortality-
dc.subject.MESHCommon Bile Duct Neoplasms/pathology-
dc.subject.MESHFemale-
dc.subject.MESHHumans-
dc.subject.MESHImmunohistochemistry-
dc.subject.MESHLymphocyte Count-
dc.subject.MESHMale-
dc.subject.MESHMiddle Aged-
dc.subject.MESHNuclear Proteins/analysis-
dc.subject.MESHPrognosis-
dc.subject.MESHProportional Hazards Models-
dc.subject.MESHTranscription Factors/analysis-
dc.titleDistinct immunological properties of the two histological subtypes of adenocarcinoma of the ampulla of Vater-
dc.typeArticle-
dc.contributor.collegeCollege of Medicine (의과대학)-
dc.contributor.departmentDept. of Internal Medicine (내과학교실)-
dc.contributor.googleauthorMin Hwan Kim-
dc.contributor.googleauthorMi Jang-
dc.contributor.googleauthorHoguen Kim-
dc.contributor.googleauthorWoo Jung Lee-
dc.contributor.googleauthorChang Moo Kang-
dc.contributor.googleauthorHye Jin Choi-
dc.identifier.doi10.1007/s00262-018-02293-6-
dc.contributor.localIdA04219-
dc.relation.journalcodeJ00445-
dc.identifier.eissn1432-0851-
dc.identifier.pmid30604042-
dc.identifier.urlhttps://link.springer.com/article/10.1007%2Fs00262-018-02293-6-
dc.subject.keywordAdenocarcinoma of the ampulla of Vater-
dc.subject.keywordCD8 T lymphocytes-
dc.subject.keywordImmunohistochemistry-
dc.subject.keywordPD-L1-
dc.subject.keywordPrognosis-
dc.subject.keywordYAP-
dc.contributor.alternativeNameChoi, Hye Jin-
dc.contributor.affiliatedAuthor최혜진-
dc.citation.volume68-
dc.citation.number3-
dc.citation.startPage443-
dc.citation.endPage454-
dc.identifier.bibliographicCitationCANCER IMMUNOLOGY IMMUNOTHERAPY, Vol.68(3) : 443-454, 2019-
dc.identifier.rimsid62519-
dc.type.rimsART-
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.